DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Rating of “Moderate Buy” from Analysts

DexCom, Inc. (NASDAQ:DXCM) has earned a consensus recommendation of “Moderate Buy” from the twenty-four research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $86.50.

A number of analysts have commented on DXCM shares. Wells Fargo & Company decreased their target price on DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday, February 13th. Mizuho lifted their price target on DexCom from $78.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, February 13th. BTIG Research reiterated a “buy” rating and issued a $85.00 price objective on shares of DexCom in a research report on Monday, March 9th. Piper Sandler reissued an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. Finally, Leerink Partners restated an “outperform” rating and set a $92.00 target price on shares of DexCom in a report on Tuesday, December 16th.

DexCom Price Performance

DXCM stock opened at $62.22 on Friday. The firm has a 50 day moving average of $69.32 and a 200-day moving average of $67.30. The company has a market cap of $23.95 billion, a price-to-earnings ratio of 29.63, a PEG ratio of 1.22 and a beta of 1.55. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45. DexCom has a 12-month low of $54.11 and a 12-month high of $89.98.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The business had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter in the prior year, the firm posted $0.45 EPS. The company’s revenue was up 13.1% compared to the same quarter last year. As a group, equities analysts expect that DexCom will post 2.03 EPS for the current fiscal year.

Insider Activity

In other news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $64.85, for a total value of $110,245.00. Following the sale, the executive vice president directly owned 112,904 shares in the company, valued at $7,321,824.40. This represents a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.32% of the stock is owned by company insiders.

Institutional Investors Weigh In On DexCom

Institutional investors and hedge funds have recently bought and sold shares of the stock. Trust Co. of Vermont increased its position in DexCom by 14.8% during the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after buying an additional 145 shares in the last quarter. CVA Family Office LLC lifted its position in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of DexCom by 2.5% in the third quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock valued at $474,000 after acquiring an additional 169 shares in the last quarter. IFP Advisors Inc boosted its stake in shares of DexCom by 24.7% during the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock valued at $61,000 after acquiring an additional 178 shares during the last quarter. Finally, Inspire Investing LLC boosted its stake in shares of DexCom by 6.1% during the third quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock valued at $211,000 after acquiring an additional 180 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.